145 related articles for article (PubMed ID: 37080709)
1. Measurable residual disease after CAR T-cell therapy.
Chokr N; Gomez-Arteaga A
Semin Hematol; 2023 Jan; 60(1):34-41. PubMed ID: 37080709
[TBL] [Abstract][Full Text] [Related]
2. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M
Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment.
Hu G; Cheng Y; Zuo Y; Chang Y; Suo P; Jia Y; Lu A; Wang Y; Jiao S; Zhang L; Sun Y; Yan C; Xu L; Zhang X; Liu K; Wang Y; Zhang L; Huang X
Front Immunol; 2022; 13():915590. PubMed ID: 35734165
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
5. MRD in ALL: Optimization and Innovations.
Pierce E; Mautner B; Mort J; Blewett A; Morris A; Keng M; El Chaer F
Curr Hematol Malig Rep; 2022 Aug; 17(4):69-81. PubMed ID: 35616771
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
8. Measurable Residual Disease Monitoring in Lymphoma.
Cuzzo B; Lipsky A; Cherng HJ
Curr Hematol Malig Rep; 2023 Dec; 18(6):292-304. PubMed ID: 37930608
[TBL] [Abstract][Full Text] [Related]
9. Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD.
Schultz L; Davis KL; Walkush A; Baggott C; Erickson C; Ramakrishna S; Aftandilian C; Lacayo N; Nadel HR; Oak J; Mackall CL
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849202
[TBL] [Abstract][Full Text] [Related]
10. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.
Paiva B; Manrique I; Rytlewski J; Campbell T; Kazanecki CC; Martin N; Anderson LD; Berdeja JG; Lonial S; Raje NS; Lin Y; Moreau P; San-Miguel JF; Munshi NC; Kaiser SM
Blood Cancer Discov; 2023 Sep; 4(5):365-373. PubMed ID: 37486974
[TBL] [Abstract][Full Text] [Related]
11. Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
Meddi E; Savi A; Moretti F; Mallegni F; Palmieri R; Paterno G; Buzzatti E; Del Principe MI; Buccisano F; Venditti A; Maurillo L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834477
[TBL] [Abstract][Full Text] [Related]
12. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
Front Immunol; 2022; 13():858590. PubMed ID: 35371098
[TBL] [Abstract][Full Text] [Related]
13. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
14. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.
Chen L; Xu B; Long X; Gu J; Lou Y; Wang D; Cao Y; Wang N; Li C; Wang G; Wang Y; Zhu L; Wang J; An H; Xiao M; Xiao Y; Zhou J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345625
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
[TBL] [Abstract][Full Text] [Related]
16. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
17. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
Wolf J; Fonseca R; Muffly L
Clin Adv Hematol Oncol; 2020 Mar; 18 Suppl 9(3):1-16. PubMed ID: 33843875
[TBL] [Abstract][Full Text] [Related]
18. Are CAR T cells better than antibody or HCT therapy in B-ALL?
Pulsipher MA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):16-24. PubMed ID: 30504287
[TBL] [Abstract][Full Text] [Related]
19. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
20. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]